There are currently 58 clinical trials in Tamarac, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including West Broward Rheumatology Associates, Inc., GSK Investigational Site, Novartis investigative site and Forest Investigative Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
02/27/2025
Locations: Care Access - Tamarac, Tamarac, Florida
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: West Broward Rheumatology Associates, Tamarac, Florida
Conditions: Rheumatoid Arthritis
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
02/27/2025
Locations: Care Access - Tamarac, Tamarac, Florida
Conditions: Alzheimer Disease
Register for Updates
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: BRCR Medical Center Inc., Tamarac, Florida
Conditions: Advanced Solid Tumor
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
02/25/2025
Locations: D&H Tamarac Research Center, LLC, Tamarac, Florida
Conditions: Type 2 Diabetes
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
02/24/2025
Locations: Infinity Life Research Group, Tamarac, Florida
Conditions: Chronic Migraine
Register for Updates
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already bei... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/21/2025
Locations: D&H Tamarac Research Center, Tamarac, Florida
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
NCT06605599
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Segal Trials - West Broward Outpatient Research Site /ID# 267947, Tamarac, Florida
Conditions: Bipolar I Disorder, Bipolar II Disorder
Register for Updates
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
NCT05193929
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Integral Clinical Trials Solutions, Tamarac, Florida
Conditions: Diabetic Foot Ulcer
Register for Updates
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135
Recruiting
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and proteinuria, including diabetic nephropathy and rare glomerular kidney diseases (primary focal segmental glomerulosclerosis \[FSGS\], treatment-resistant minimal change disease \[TR MCD\], primary immunoglobulin A nephropathy \[IgAN\], and primary membranous nephropathy... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: D & H Tamarac Research Center, Tamarac, Florida
Conditions: Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: Advanced Research, Tamarac, Florida
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514
Recruiting
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Summit Therapeutics Research Center, Tamarac, Florida
Conditions: Non-Small Cell Lung Cancer
Register for Updates